SecBot SecBot
SECBOTREPLAY Home › Report › SLS

SLS · $150M public offering priced

SELLAS Life Sciences Group, Inc. · 8-K filed Nov 20, 2026 at 06:01 ET

At the news

BEARISHIMPACT 6/10

8-K filed Nov 20, 2026 at 06:01 ET

SELLAS Life Sciences priced a $150M underwritten public offering of 11,538,462 shares at $13.00 per share, with a 30-day underwriter option for up to 1,730,769 additional shares. The offering closed on November 20, 2026, raising approximately $161.8M in net proceeds including the full exercise of the option, to fund clinical development and commercialization activities following positive Phase 3 REGAL trial results.

  • Priced 11,538,462 shares at $13.00 per share, a 27.6% discount to the prior day's $17.95 close
  • Underwriters have a 30-day option to purchase up to 1,730,769 additional shares at the same price
  • Net proceeds of approximately $161.8M including full exercise of the option
  • Underwriters include J.P. Morgan, TD Cowen, Mizuho, A.G.P./Alliance Global Partners, and Maxim Group

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access